Why Cryopreservation is No Longer Science Fiction with Until Co-founder and CEO Laura Deming
31 min
•Jan 29, 20263 months agoSummary
Laura Deming, co-founder and CEO of Until, discusses the science and business of reversible cryopreservation—freezing and reviving living tissue. The company aims to first solve organ transplant logistics by preserving organs longer, then progress to whole-body cryopreservation for medical hibernation when life-saving treatments become available.
Insights
- Cryopreservation is technically feasible at small scales (embryos frozen 30+ years) but remains under-resourced due to social perception as science fiction rather than legitimate medical research
- Engineering and biology trade-offs exist in cryopreservation: better cooling/rewarming engineering reduces need for toxic cryoprotective agents, making the problem more tractable than pure biology alone
- Temperature as a conceptual tool provides unusual leverage in biology—it links molecular motion to measurable parameters, enabling physics-based theoretical approaches rarely applicable to other biological problems
- Transplant medicine has massive inefficiencies: organs expire quickly, surgeons operate sleep-deprived, patients live under house arrest near hospitals, and matching happens at the last minute with limited information
- Longevity and aging occupy a 'social blind spot'—not classified as diseases despite being addressable through technology, creating funding and research attention gaps independent of technical feasibility
Trends
Longevity science transitioning from fringe to mainstream academia and consumer interest, reducing stigma around aging-focused researchVenture capital increasingly targeting 'antimemetic' problems—technically feasible but socially misunderstood areas with low competitionOrgan transplantation becoming optimization problem: time-based constraints (organ viability windows) are primary bottleneck, not surgical techniquePhysics-based approaches gaining traction in biotech: leveraging fundamental physical principles (temperature, thermodynamics) for biological engineeringMedical hibernation reframing from life extension fantasy to practical critical care: near-term use cases (bridging treatment gaps) more credible than long-term scenariosCryopreservation field consolidation: academic pioneers (Greg Fahey, John Deschoff) establishing proof-of-concept; venture backing now scaling engineering infrastructureBiotech founder profile shift: technical depth (first-principles thinking, physics literacy) becoming competitive advantage over pure biology backgrounds
Topics
Reversible cryopreservation technology and ice formation preventionOrgan transplant logistics and time-based constraintsCryoprotective agents and toxicity trade-offsMedical hibernation for terminal illness treatment windowsWhole-body cryopreservation technical roadmapBrain preservation and neuroscience unknowns in cryopreservationVitrification and cooling/rewarming rate engineeringLongevity research funding and academic legitimacyVenture capital allocation to 'antimemetic' problemsTransplant patient experience and quality of lifeMolecular visualization and science educationTemperature as conceptual lever in biological systemsStochastic ice nucleation and probability modulationRat model progression for whole-body cryopreservationClinical trial timelines and patient eligibility windows
Companies
Until
Laura Deming's company developing reversible organ cryopreservation for transplants and whole-body medical hibernation
Longevity Fund
Laura Deming's previous venture fund focused on longevity research and drug development
People
Laura Deming
Co-founder and CEO of Until; previously founded Longevity Fund; expert in cryopreservation and longevity research
Hunter
Co-founder of Until; derives fundamental physics principles from first-principles; leads technical architecture
Greg Fahey
Cryopreservation pioneer who demonstrated reversible kidney cryopreservation in rats with full functional recovery
John Deschoff
Academic researcher in cryopreservation field; contributed foundational work on reversible organ preservation
Quotes
"What if you could take someone who is on their deathbed and find some way to hibernate them until the sort of critical cure for the disease comes online?"
Laura Deming
"Making time not a variable changes the whole paradigm."
Laura Deming
"The problem speaks for itself. Water expands when it forms ice. That's just hard for your tissue to take without substantial damage."
Laura Deming
"We already reversibly cryopreserve tissue, including human tissue, all the time. And we do it for very long time periods. There are kids who were literally cryopreserved for 30 years as tiny embryos."
Laura Deming
"You can trade off engineering difficulty and biological difficulty to a non-zero degree. That's not true for most problems in biology. And it gives you a lot of leverage on the problem."
Laura Deming
Full Transcript
What if you could take someone who is on their deathbed and find some way to hibernate them until the sort of critical cure for the disease comes online? The ability to freeze time for humans. I didn't actually think that was something you could go work on, so apparently it is. Our long-term goal is reversible whole body cryopreservation for medical hibernation. But in the near term, what we work on is reversibly cryopreserving single human organs to help transplant patients get organs more efficiently. Making time not a variable changes the whole paradigm. One thing I love about the field of cryopreservation is I think like the problem speaks for itself. Water expands when it warms ice. That's just hard for your tissue to take without substantial damage. And the cool thing is that there's sort of a temperature below which ice formation stops happening. So basically if you can traverse and you can get below that without ice formation, then you're good. We already reversibly cryopreserve tissue, including human tissue, all the time. And we do it for very long time periods. There are kids who were literally cryopreserved for 30 years as tiny embryos. And so the main question is not, is this possible to do at all? Is it possible to scale up? Given that's true, why don't you think it's been worked on? Hi, listeners. Welcome back to No Priors. Today, I'm really excited to be here with Laura Deming, previously the founder of the Longevity Fund, and now the co-founder and CEO of Until. We're going to talk about how Until is progressing the frontier of reversible cryopreservation, or freezing living things and waking them back up, beginning with human organs progressing to small animals and hopefully making progress on the whole body. It sounds like science fiction, but we'll talk about some of the scientific challenges, where we are today, and the implications if this is possible. Thanks so much. Welcome, Laura. Laura, thanks so much for doing this. Yeah, thanks for having me. I've been so looking forward to this since our Pantheon Watch sessions. We're talking about upload and the nature of consciousness, but one thing that you don't know is that my like very long ago wished for technologies that I wanted to exist were telepathy and like upload and the ability to freeze time for humans. I didn't actually think that was something you could go work on. So apparently it is. How do you end up working on that or being interested in longevity at all? There's two different questions. So yeah, I come from longevity background, but in my mind, like reversible cryo preservation is applicable a bit outside of that as well. I don't know. I mean, I think I'm really obsessed with areas that feel like they should be worked on, but aren't. And, you know, when I was a kid, I think naively just growing up, that seemed really obvious for longevity. And it's really surprising to realize that, you know, it's not the case that most people like are working on that explicitly as a goal. And in fact, that like, it's kind of like, I think longevity and aging kind of occupy this weird realm where because they're not like explicitly diseases in a way that's fully socially recognized yet, they're not seen as valid to work on. But like that's not really for, I think, technical reasons on some level. It's more for like classification reasons because like, you know, you can extend the lifespan of like sort of many different organisms using technology and how much can do that in humans. We have no idea. And, you know, it could be very small for technology, but sort of like I think longevity is interesting because it feels like an area where there's a social blind spot around something. And I find those very interesting. Perhaps I was just I'm sure this is true. not very observant as a school-aged child, but I don't think I even understood aging was like a concept that I should consider at all. And so how did you end up thinking about it in any depth? I grew up in a pretty odd setup. So, you know, I was in New Zealand. I was homeschooled. I didn't really have a, like, I didn't go to a normal biology class. I was kind of, you know, by myself in the house. I imagine you like staring at a field of sheep and then being like, someday we're going to get old. I should do something about this. Yeah, no, that would have been the farm that we had for a little bit. But I remember one thing that was really stood out to me was at some point when I was a kid, I was thinking about how long people in my life were going to live and how old they were. And for some reason, it made a lot of sense to me that everyone should live until they were 10 years old and then die immediately at 10 years old. Like I just that like that seemed like some hypothesis. I didn't really know how old people were. And so working backwards, I was like, oh, my dad must be like, you know, maybe eight and my mom's younger than so like maybe seven but i think one thing that was really striking was realizing that we don't all live until a certain age and then we die in fact we don't you know know like what determines how long we live like that that was very interesting right this idea that like i was like if we all lived until 10 years old and then we died immediately at town like i would feel much more confident with the idea that like longevity is some kind of immaleable like hard limit but they do that like there was uncertainty about that it's really interesting and sort of like what are the factors behind that uncertainty? So I'm going to fast forward through a bunch of like lab work you did and going to MIT and being a Teal Fellow, like why a longevity fund? Me just being very literal, like at the time that I was interested in longevity, I think if you ask the average person in the field, like what's the big problem? Most people would say, well, we just can't get enough funding for our projects. And so that's the big problem. And I just took that literally like when I was a teenager. So I won't have that problem. Yeah, I was like, I should just get a lot of money to like help push longevity drugs forward. And the name for that happened in venture capital fund, but it definitely wasn't working downstream of the idea of venture capital. Like that came after this idea of like just getting money for projects that should have money and it didn't. You did this for a number of years. What triggered the like sort of change in how you were going to spend your attention to cryopreservation? I think just like cryopreservation is one of the coolest, I think it's not like to pardon the pun, but I think it's one of the coolest, most interesting, like, best problems ever. Like, I think, like, I mean, from so many different angles, like, I think you've heard such counterfactual impact. Like, if you're obsessed with, like, just technical delight, like, just raw sheer, like, technical interest and diversity and, like, a lot of technical parts of the problem. And then also, I think, from perspective of social impact, like, I'm just, it was just, it's such an interesting problem from, like, how it's perceived and then, like, what are the different factors of that? It was, like, zero to one. It was, like, the, I remember just seeing the problem clearly for the first time. I mean, a lot of the people in my life, I think had been aware of it, but I just, it took me so long to really, I think, see it clearly for myself. But then it was just like zero to one of like, this is the only thing that I could imagine pouring the next decade of like my work into it. That was after I kind of done kind of the first set of work with the fund. I was kind of like thinking like, what is the next like big thing? With your co-founder Hunter, was it like an immediately obvious, yes, we should work on this together? He's one of the few people where if I ask him a question, like he'll come back the next day and giving an answer. He's literally thought through from first principles, like what the correct answer is. Like, I remember at some point I realized that he'd written a doc on like the principles of like, you know, craft preservation. Like most people, you know, like, like would write that from the literature or kind of like citing different sort of sources at various levels of granularity. Hunter went back and like re-derived fundamental laws of stat and mech as part of like, this is what you should know in craft preservation doc. Like I really admire how much he builds up from like really simple models to try to create coherent like technical pictures that are more complex. He's like the most fun, interesting, best person to work with ever for sure. And it wasn't a hard sell like we should go work on this problem in particular. It was not a hard sell, but it was not an interesting way. So I think one thing that I like love about the field of cry preservation is I think it's very compelling. Like if you like hard, like it's one of those things where if you like the problem speaks for itself and so I remember telling Hunter about it in our first call and he basically was like oh I don't buy it he told me later that he didn't tell me in the call but then he went off and thought about it for a couple days and like really thought about like what we knew about ice formation like did you know some like basic back of the envelope math and came back and he was like oh wait this seems like actually feasible or like this seems like it in the realm of possibility in a way that is very different from my initial intuition. And that sort of like conjugation is just so interesting to me. Maybe it's useful to zoom out and just say, like, what is the goal of Until? I would think about our goal as trying to create a new form of critical care. The example that I would give that is sort of the core of the company is there's some years where certain diseases such as like metastatic melanoma go from being like sort of in a single year like metastatic melanoma went from being something that you had like a six to nine month prognosis like less than a year of expected survival to with like you know new combination immunotherapies you might have a decade plus of expected survival or like 50 percent of people sort of surviving over a decade um you know without getting sort of uh death from melanoma in fact there was starting to have other things at that point the tagline is like single years can make the difference between a patient dying of internal illness and like living long enough to make the critical cure. But right now, like there's no way to press pause on their biological time. Like what if you had an ambulance for the future, right? Like what if you could take someone who is on their deathbed and, you know, find some way to, you know, just sort of hibernate them basically until the sort of critical cure for the disease comes online. And like, you know, and in this context, we're not talking about necessarily decades or kind of like, you know, much longer than that. Initially, it's just kind of in the context of like when there's a window where you could imagine like a critical trial is being done for a drug that were they eligible for it could make a huge difference for their disease. To give an example of like the need to, it's like my sort of co-founder's father-in-law had this happen to him in the sense that he got sort of advanced cancer that would have been treatable or addressable by a therapy that came out basically a couple months after he was no longer eligible for the therapy. And he like missed, you know, the critical clinical trial by like, you know, a couple of months. And so it's sort of like that level of urgency that like someone in that position shouldn't have to, you know, miss a critical therapy because there's a couple of month difference in like when they got their sort of disease and when the therapy came available. And from a just like product perspective, that means you need to do whole body cryopreservation. Yeah. So, so like to give context on technically how we think about this problem. So our long-term goal is reversible whole body cryopreservation for, you know, medical sort of hibernation. But in the near term, what we work on is reversibly cryopreserving single human organs to help transplant patients get organs more efficiently. I want to come back to like all of the technical challenges here and where we are and what you think the next milestones are. But because you describe it in the context of medical use, like I'm going to be honest, as a kid, I was like, well, I want to be able to freeze time because I want to be able to go to Mars too. Or you said, because you've worked on longevity with this perspective, like aging is, you know, it could be considered a disease, a health state we should work on that is credible medical science. So how do you think about those other use cases? So an interesting thing when you start to think about like actually applying technology is sort of what's the experience of the person, not just kind of technically for the disease, but socially. So like one of the number one reasons most people wouldn't do medical hibernation and especially that it wouldn't be like for the most part a recreational thing is that you know you i think a lot of people view themselves in part defined by their social context so like when when you say recreational thing you mean because like you you just you think of that as uh going to mars as a recreational use case oh no sorry i i think this case what i'm thinking of is you know some people might imagine that they would love to skip into the future just to see what happens you know and maybe you know like have their same amount of number of years of life, but like be future shifted by some amount of time. Yes. But the number one reason that most people wouldn't do that and are also just very wary of the idea of hibernation for themselves is, you know. I can't take everybody with me. Yeah, exactly. It's a city that like you kind of find yourself by the people around you. And so I think I think like, you know, those kinds of use cases like going to Mars, those are all kind of things that could happen and could happen with or without hyperlacer could happen. We'll work for hibernation technology for certain like definitions of mind. um but i think the thing that a lot of people will face is just like this question of like is it worth you know traveling so far to give up my current social context and that will put a limit on like how much people want to use this for like i think there's like a real cost that that kind of you incur and so it's in my mind it only makes sense for like really serious use cases initially um where like you literally would die if or like you know because yeah because you're kind of putting on the line like your current like all of your current social reality and like how that will evolve without you versus like you know this other thing that you might want but i mean a lot of people might want to go to Mars, you know, like context, because I think I'm a little, yeah, the cost is pretty significant. It's very hard to know what we want, though. Like a lot of people might make that decision whether or not, you know, their ultimate happiness is higher. It's fair. Maybe you can just break down how you think about the challenges scientifically, right? Versus, I think, to maybe even Hunter's original reaction, like, sounds like science fiction. I don't know if you can go work on that thing. Yeah. Right. And so if it's, you know, crystal formation or whatever the set of challenges and what sequence you think you should solve them. I see. Yeah. Maybe I can just give a series of facts that I think together sort of make the problem super interesting. So one fact is that ice formation is a stochastic process. So if ice just formed unilaterally in any given material past a certain point of temperature, like, you know, just like go from zero to one, it's like 100% ice. Like that might be kind of hard to think carefully about technically, but ice sort of forms through a process of random nucleation and then extension. And this is cool because you can modulate the like sort of nucleation, the rate of nucleation and extension to then modulate the probability of ice formation. And because it's probabilistic, if you can do that well enough and you can sort of spend minimal time in the temperature range where ice can nucleate, then that gives you a shot at sort of preventing a lot of ice formation. So like the number one tagline would be like, avoid ice at all, or like sort of avoid as much as possible. There may be some, like I think some people might be working on technologies to cry preserve with some sort of like ice formation, but we're focused on regimes where you're basically trying to avoid as much ice formation as possible. Just for the non-biologists, you know, ice formation is bad because it breaks all the cell membranes. Yeah. So ice formation is bad because water expands when it forms ice. And that's just hard for your tissue to take without substantial damage. So you want to avoid ice formation. And the cool thing is that there's sort of a temperature below which ice formation stops happening. So basically, if you can traverse, let's say, you know, going below zero degrees or less through to around minus 130, and you can get below that without ice formation, then you're good. And the interesting thing is at that point, you're good for quite a long time. So there have been human embryos that were reversibly cryopreserved for, the latest record was over 30 years, and then rewarmed and sort of viably used to create pregnancy. And then, you know, sort of like there are kids who were literally cryopreserved for 30 years as tiny embryos. And so that's the last thing, which was very surprising to me, which is that like we already reversibly cryopreserved tissue, including human tissue, including cold body human tissue at that very, very small, you know, a couple hundred cells stage all the time. And we do it for very long time periods, which I honestly like would have first principles been stuck on. Is this possible to do at all? Is it possible to scale up to a large complex biological system that has a lot of vasculature where you're dealing with different material properties, where you have to think a lot about like perfusion and how to sort of diffuse chemicals in and out and how to like get heated out quickly enough So the idea that you could pause all molecular motion and then randomly restart it and even a cell would survive that you know like from French principles to me used to seem crazy But we know that works Yeah it like wait wait wait we just we already like scientists just tried it and it worked. And so now the problem is like scaling that up and doing it in a way that's compatible with like, you know, tissue health. Yes. I think one of the things that was most wildly surprising to me, like being in your lab a little while ago is how much it looks like people were working on what I'd consider to be like engineering problems around like, oh, how do we get something to warm quickly and safely enough versus let me go work on this therapeutic? Yeah. So actually, I feel like there's this part of the problem that I've been trying to explain externally for a long time. Every time I try to explain it, I think it comes off as like not specific or something, but it is actually one of the core reasons why I think the problem is interesting to work on, which is that like you can trade off like engineering difficulty and biological difficulty to a non-zero degree. Like not 100%, like you can't just use engineering to solve the problem. You absolutely have biological questions and like those questions could come out in the negative for some of these cases. So like that's not saying you can just make an engineering problem, but like you can make your life easier on the biology front by building better engineering tooling. And the fact that that's possible is a huge deal. Like that is not true for most problems in biology. And it gives you a lot of leverage on the problem. This is probably interesting to maybe only like 5% people watching this, but like I think that I'm obsessed with is just the idea like temperature is such a beautiful conceptual tool right it's like temperature as an idea is something that in physics took it like took physicists hundreds of years to come up with it links like molecular motion to a high like a single high level measurable parameter and just tuning temperature like sort of tells you about almost like the relative passive time of like molecules at the nanoscale like that's that's a highly non-trivial sort of conceptual lever to have on a problem and in biology one of the biggest problems is like it's really hard to find powerful conceptual levers on sort of like for like nanoscale for for manipulating like the nanoscale that have anything approaching that degree of sort of leverage basically what that gives you is like you can apply a lot of theoretical sort of um a lot of theoretical toolkit used in physics to model parts of this question in ways that are actually useful and it is just not true that you can use like equations from physics to think usefully about almost any other problem in biology there are questions like the content and the like medical devices but like um in a in a context where you're talking about like changing the course of terminal illness um which this one is interesting because this doesn't mean i'll change it but like it gives you the possibility of some more time i think it's one of the most important things about the the problem i don't understand how to explain it in a way that is clear but i think it's like one of the most important things to understand about the problem. Yeah. Maybe if I think about actually applying it, like just very concretely to what you are doing, like if it is challenging from a, you know, organ preservation biology perspective to have a organ reheated or sorry, rewarmed like evenly throughout, then maybe the thing to do is to like change the surface area to volume ratio of like your heating device or distribute the heat in different ways without like changing your understanding of the biology, but just with new devices and technologies that you invent from the engineering perspective. Like that actually seems like a very simple example. I realize you're implying a like more fundamental view of like why temperature is just such a interesting framework to be working on from both an engineering perspective and a biology perspective. And there's like trade-offs where you put your effort here. But I think that's actually that's something that like didn't did not occur to me at all coming into your lab and learning more about until I was like oh it's actually like a to some degree much simpler problem than I understood to the point of like well if you can just reduce and preserve time reduce and increase temperature in these ways that are perfect through this organ it's going to work Right. Yeah. So let me restate that and then give one caveat just to make sure that I can do it correctly. So a way that you can talk about the tradeoff between engineering and biology is that with engineering, you can modulate cooling and rewarming rate just to certain extents. And then that can then change like how much what we call a crop-tractive agent or kind of chemical that modulates ice formation you add to the system. And you want to minimize the concentration of that crop-tractive agent. Because it can be toxic. Exactly. And so as you increase cooling and rewarming rate, a.k.a. spending therefore minimal time in kind of the dangerous zone of ice formation, you can correspondingly decrease the concentration of crop-tractive that you're putting in. But if you could instantaneously cool and rewarm, then you wouldn't have to put any CPE in. But that's not something that we're default assuming is feasible for a large system. So there's still always going to be a component of biology, aka like how tissue responds, especially from a toxicity perspective, to like a new chemical agent. Where are you now in this progression? Like, should I think of it as like there's a kidney and then it seems like quite a large jump to a small animal, but maybe it's not? Yeah, so we work on the two in parallel. So we both work on scaling up heart preservation and rewarming technologies to kind of human organ scale. And also in parallel, we work on sort of whole rat reversible hibernation and translating technologies over from sort of what we learn on the kidney side into the rat context, as well as doing things specifically for rat. When you started the company, did you have a timeline in your own mind? So I think initially I was like, we could maybe make some progress and hopefully make some good products. But like the idea of full body cryopreservation felt like that would be really far out if that was possible. I mean, I think I definitely still wouldn't put like a near term timeline on it, but I feel like we have a much clearer roadmap, at least to get to begin to get there. And the first steps seem faster than I would have imagined, if that makes sense. But the big unknown to get to whole body reversible is the brain. It's unclear. Like the brain can withstand a lot of change and does withstand a lot of different types of damage or change with age, for example. But it's unclear whether like what kind of injury the brain could sustain in the context of like a whole body reversible core preservation protocol. And then like what level of fidelity it's possible to do. So like that to be clear is a big unknown on the neuroscience side. How do you recruit and like lead in a company that has like, let's say, an unclear like timeline around a really big scientific goal like that? Like in terms of both finding people that are the right fit, motivating them. And how do you think about urgency in that context? I mean, I think we have a pretty clear timeline for our first product, which is like get a reversibly cryopreserved. So basically transplant patients today surprisingly frequently miss organs that are on route to them because there's a timing problem. so like you know organs expire very quickly after they become available from a donor that's very unfortunate yeah and it's crazy because it's like they're the they're like one of the most precious resources we know of and yet like people regularly charter private jets you know like it's like you're putting a surgeon on a private jet to go pick up an organ get it back to the patient in time like and you're doing all that at the last minute and scheduling the patient for surgery at the last minute so the patient has to wait within like a two-hour radius of a transplant center with a pager on them or like a notification device at all times and so So the first product that we're aiming towards is just being able to pause time for the organs. The patient doesn't, you know, you can take as long as you need to get the organ to the patient. And that's very near term. That's not long term ethical. That's like we're aiming to get that into like prequel studies and into the clinic as quickly as possible So I think it helps to have a very concrete goal that clearly is relevant to a long term goal I think another thing that was inspired just about that product was like if we at all talking about full reversible cryopreservation and we can make a dent on that problem like There's no version of not going through it. Yeah. It's sort of the same as where it's like, if you're serious, that should be doable. And if like, you can't do that, then like you're not the company to like do the long-term thing. So that was nice for us to like have a very clear benchmark for ourselves of like, you know, are we correct that this is attractable technology on that scale? I guess like is it is it a challenge or to lead beyond that because everybody understands the company has a broader mission or is it just focus on step one? I think I think there there there's the possibility that's difficult. But I think right now I feel good about sort of our ability to compete around that, which is like I think if we were like it's 100 percent possible to do whole body risk for care preservation. There's no question. We're certain. Like then we would just be bullshitters and then we like we wouldn't be able to recruit because it's you know, there's a lot of technical risk and there's a lot of uncertainty between here and there. I think we can't accurately expose the models that we use to think about the problem. You know, like why we think that this is at all possibly in scope and like, you know, what we're testing to, you know, sort of trying it closer to there. And I think the problem is interesting enough that, you know, some of the hundreds are like really good people tend to be skeptical at first because there's an intuition that it shouldn't work. But then like they'll see a lot of data very quickly where it's like, wait, I wouldn't have thought that was possible intuitively, but that seems to be possible. And so like, let me think about some first principles. What's another data point that you think matters besides like embryos can be frozen? Embryos can be reversibly cryopreserved. And there's work from the existing cryopalgae community. So from John Deschoff's group and then predated by that. Also, you know, Greg Fahey has done excellent work sort of looking at reversibly cryopreservation in kidneys and showing like you can reversibly cryopreserve a kidney, rewarm it, put it into a rat that does not have another kidney and that rat returns to normal function after about a month. so it's sort of like you know even just on the whole mammalian organ scale like this is not a problem that's entirely out in the wilderness it's something that like um is even academically tractable right now given that's true why don't you think it's been worked on um i realize i'm asking an answer for other people but i'm like well that's very odd yeah i mean i think even the field of like organ reversible crop preservation really had trouble for a while attracting the resources that would be required to scale it. And I really give a lot of credit to the field pioneers. Like, you know, Greg, you know, is an incredible example of somebody who fought tirelessly to make this field a reality and sort of make vitrification a thing that people were taking seriously. And, you know, like through a long period where I think it just wasn't kind of something to focus on. But I don't know how to put it, but like in venture, like I think my whole job sort of in that part of my life is like picking trends that like sort of feel like, oh, this thing just feels weird or it seems kind of hard to think about. But technically, like, there's nothing kind of that corresponds to that. And I think, like, for example, like whole body reversible car preservation, like now seen as just much more kind of reasonable, but whole body reversible car preservation, definitely an area where I think there's just like so much possibility for conflation with like really extreme, like it's hard to talk about it rationally. People either like love it and they love it so much that they won't question it. Or it's like they're worried that thinking about, that associating with it is a little bit too science fiction for kind of where it might be optimal for them to be focused. And so I think like, I'm kind of dancing around some things that like are still a bit antimemetic around it, but yeah. The study of longevity has become much more mainstream over the last five years or so, both academically and in terms of consumer interest, Right. And I think those two things are linked. Do you hope that happens with cryopreservation? Aging becoming something that like one of the best, like someone who's seen as one of the best, like next generation professors chooses to work on without shame or fear of like not getting a grant is great. that part of aging that being on stream is great and like i definitely hope that that happens for cryopreservation specifically also for cryopreservation of like variety of tissues including like neural tissue um and including like things related to um whole body work not exclusively but like like you can basically that those topics are like um seen as something that you're like it's fine to work on maybe uh just like if you go to paint a picture of um organ transplantation is transformed by, you know, until like in what ways? Like, how do you think that will change either what type of care patients can receive or even do you think that has any impact on how people think about the speed of medical research? I think the thing that feels the most compelling for me is just like the experience of the transplant patient. It's really, I think, constricting. It's like you're waiting for a life-changing surgery and you have no idea when it will even be scheduled, you know and you can't go on vacation or really leave like and you have to like move you have to be like close to the place where you will get surgery and you can't leave a certain radius of like travel distance to that place for fear of losing out on your life-changing surgery like that is such a surgery center house arrest yeah that's such a crazy proposition and then i also think um you know right now for matching it's like everything's done at literally the last minute it's like someone dies an organ comes available and like you're just kind of calling around trying to find like what patient is available to get this organ and you don't have that much time to make the optimal match right it's sort of like like who can get to the hospital yeah yikes um and so i think just like one uh sort of transplant surgeon that that we've been working with the way he described it was just like just making time not a variable changes the whole paradigm i don't think that will happen overnight obviously but like i think the dream would be that like everyone ecosystem has the time they need to like you know make the best possible decisions sort of like do things in a way that feels the best for them like surgeons have to stay up overnight the same day that they flew out to get the organ to do the surgery. You know, they can like wait sort of until it's like the best time for them instead of doing it like literally, you know, like as soon as they land, like they go into operation like that. It's sort of something that when you really think about it, it's like it's amazing that, I mean, it's incredible that like everyone is operating this way right now. Maybe to close up, if we broaden the scope a little bit, are there other problems that are in, let's say, biology, medicine, science technology that you think are like worth working on and interesting and perhaps feasible, but people are not looking at as much as they should be? You know, maybe not even making a value judgment, but that you're curious about. Aesthetically, I'm just really curious about like how to represent the molecular world in a way that people can understand and engage with. Like, I think it's just such a cool and beautiful thing. It's like, you know, we're talking about kindergarten like roles earlier. It's like this beautiful kindergarten like feels in my mind very colorful, even though it's like not literally sort of place to play around. And I think most people experience it as like flat triangles and squares in a biology textbook where it's like you know there's an arrow between like this triangle and this triangle it's just like doesn't make any conceptual sense and it's like confusing and annoying and so i'm just like i personally i'm really curious about like how to erupt in the muckler world in a way that is really compelling and feels super exciting from an education perspective i think it is artistically cool if it's educational but i think it's it's more just because i think it's so beautiful it's like if you've never seen a tree it's like being able to see a tree it's like that would be so great right you know it's like this complex fractal thing and all this light falling through the the sort of tree branches. And I think like the popular world is like that. It's just, it's a kind of view that's not made accessible to most people. It's hard to conceptualize and you have to like do some amount of studying to sort of like build the world in your mind correctly. I look forward to finding that art. Thanks, Laura. Thanks for having me. Find us on Twitter at NoPriorsPod. Subscribe to our YouTube channel if you want to see our faces. Follow the show on Apple Podcasts, Spotify, or wherever you listen. That way you get a new episode every week. and sign up for emails or find transcripts for every episode at no-priors.com.